Shree Ganesh Biotech India Ltd Hits All-Time Low Amidst Continued Downtrend

Market Performance and Price Movement

On the day of the new low, the stock declined by 3.33%, slightly underperforming the Sensex’s 2.85% fall but outperforming its own sector, Agriculture, which dropped 3.86%. Despite this relative outperformance within its sector, the stock remains deeply entrenched below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained bearish momentum.

Over the past year, Shree Ganesh Biotech’s stock has lost 42.00%, a stark contrast to the Sensex’s positive 3.15% gain. The decline extends over longer periods as well, with a 3-year loss of 50.43% against the Sensex’s 28.20% rise and a 5-year plunge of 90.09% compared to the Sensex’s 50.26% increase. The stock’s 10-year performance remains flat at 0.00%, while the Sensex surged over 209.24% in the same period.

Financial Metrics Highlight Weak Fundamentals

The company’s financial health continues to reflect challenges. Shree Ganesh Biotech’s Mojo Score stands at a low 17.0, with a recent downgrade from a ‘Sell’ to a ‘Strong Sell’ grade on 8 Aug 2024. This downgrade underscores deteriorating fundamentals and heightened risk perceptions.

Operating losses have persisted, contributing to a weak long-term fundamental strength. The company’s ability to service debt is notably constrained, with an average EBIT to interest coverage ratio of just 0.82, indicating insufficient earnings to comfortably cover interest obligations. This ratio is a critical indicator of financial stability and the current figure signals vulnerability in meeting debt commitments.

Profitability metrics also remain subdued. The average Return on Equity (ROE) is a modest 2.62%, reflecting limited profitability generated from shareholders’ funds. Additionally, the company reported a negative EBITDA, further emphasising the financial strain.

Operational and Liquidity Indicators

Liquidity concerns are evident from the company’s debtors turnover ratio, which stands at a concerning 0.00 times for the half-year period, indicating difficulties in collecting receivables. This metric suggests potential cash flow constraints that could impact day-to-day operations and financial flexibility.

Recent results for the quarter ended December 2025 were flat, showing no significant improvement in revenue or profitability. Over the past year, profits have declined by 115.5%, a severe contraction that aligns with the stock’s steep price decline.

Shareholding and Sector Context

The majority of Shree Ganesh Biotech’s shares are held by non-institutional investors, which may influence liquidity and trading dynamics. The company operates within the Pharmaceuticals & Biotechnology sector, which has experienced mixed performance recently. While the Agriculture sector, closely related in some operational aspects, declined by 3.86% on the day, Shree Ganesh Biotech’s stock outperformed this sector by 2.2% despite its own negative movement.

Comparatively, the stock’s weekly and monthly performances have been weaker than the Sensex, with a 1-week loss of 4.92% versus the Sensex’s 4.45% decline, and a 1-month loss of 12.12% against the Sensex’s 8.80% fall. Year-to-date, the stock has declined 6.45%, slightly better than the Sensex’s 10.03% drop, though this is within a context of overall weakness.

Valuation and Risk Assessment

Shree Ganesh Biotech is currently trading at valuations considered risky relative to its historical averages. The combination of negative EBITDA, weak debt servicing capacity, and low profitability metrics contribute to this elevated risk profile. The stock’s prolonged underperformance over multiple time horizons highlights the severity of its valuation challenges.

Despite the recent price hitting an all-time low, the stock’s performance over three months (-6.45%) has been less severe than the Sensex’s 9.44% decline, indicating some relative stability in the short term. However, the longer-term trends remain unfavourable.

Summary of Key Financial and Market Indicators

To summarise, Shree Ganesh Biotech India Ltd’s stock has reached an unprecedented low of Rs.0.58, reflecting a sustained downtrend over multiple years. The company’s financial metrics reveal ongoing losses, weak debt coverage, and limited profitability. Its Mojo Grade of Strong Sell, downgraded from Sell in August 2024, further highlights the challenging environment.

Performance comparisons with the Sensex and sector indices show consistent underperformance, with the stock losing nearly half its value over three years and more than 90% over five years. Liquidity indicators such as the debtors turnover ratio at zero times raise concerns about cash flow management.

While the stock’s recent relative outperformance against the Agriculture sector on the day of the new low is noted, the broader trend remains negative. The company’s shareholder base is predominantly non-institutional, which may affect trading volumes and price stability.

Overall, the data portrays a company facing significant financial and market pressures, with its stock price reflecting these realities through historic lows and challenging valuation metrics.

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →